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Background. The aim of the study was to present dosimetric comparison of image guided high-dose-rate brachy-
therapy (IGBT) with volumetric modulated arc therapy (VMAT) for head and neck cancer regarding conformity of 
dose distribution to planning target volume (PTV) and doses to organs at risk (OARs).
Patients and methods. Thirty-eight consecutive patients with T1-4 mobile tongue, floor of mouth and base of 
tongue cancer treated with IGBT were selected. For these patients additional VMAT treatment plans were also pre-
pared using identical computed tomography data. OARs and PTV related parameters (e.g. V98, D0.1cm3, Dmean, 
etc.) were compared. 
Results. Mean V98 of the PTV was 90.2% vs. 90.4% (p > 0.05) for IGBT and VMAT, respectively. Mean D0.1cm3 to the 
mandible was 77.0% vs. 85.4% (p < 0.05). Dmean to ipsilateral and contralateral parotid glands was 4.6% vs. 4.6% and 
3.0% vs. 3.9% (p > 0.05). Dmean to ipsilateral and contralateral submandibular glands was 16.4% vs. 21.9% (p > 0.05) 
and 8.2% vs. 16.9% (p < 0.05), respectively.
Conclusions. Both techniques showed excellent target coverage. With IGBT dose to normal tissues was lower than 
with VMAT. The results prove the superiority of IGBT in the protection of OARs and the important role of this invasive 
method in the era of new external beam techniques.
Key words: head and neck cancers; image guided high-dose-rate brachytherapy; volumetric modulated arc thera-
py; dosimetric comparison
Introduction
 Head and neck (H&N) cancer is an excellent indica-
tion for radiation therapy (RT) which is an organ 
preserving method maintaining the quality of life of 
patients. Brachytherapy (BT) with or without exter-
nal beam RT (EBRT) can play an essential role in the 
treatment of certain tumor localizations in the H&N 
area  except cases with bone invasion or proximity 
of large vessels, delivering an ablative dose to the 
target volume while sparing the critical and normal 
tissues - due to the rapid dose fall-off - which is not 
safely feasible with EBRT alone.1-3 Image guided 
high-dose-rate BT (IGBT) with computed tomog-
raphy (CT) and/or magnetic resonance imaging 
(MRI) has been implemented improving the effica-
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cy of BT.4 IGBT decreases irradiated doses to critical 
structures without compromising target coverage.5 
However, IGBT is an invasive procedure requiring 
special skills and interdisciplinary co-operation 
with a H&N surgeon, as well as patience on the 
part of patients who have to endure e the insertion 
of catheters.6,7 Recently, intensity modulated RT 
(IMRT) has been introduced in clinical practice and 
achieved higher dose conformity with better organs 
at risk (OARs) sparing compared to 3-dimensional 
conformal radiation therapy.8 Volumetric modu-
lated arc therapy (VMAT), an improved technique 
of IMRT offers reduced irradiation time compared 
to IMRT.9 Nowadays IGBT meets the challenge of 
high precision EBRT such as VMAT, which is a 
non-invasive modality and does not require special 
skills to deliver a high conformal dose to the target 
volume while saving critical normal structures. To 
our knowledge no detailed dosimetric comparisons 
of IGBT with VMAT have so far been reported in 
the H&N region, such publications are available 
only for breast and cervical cancer.10,11
The purpose of this study is to present a dosi-
metric analysis regarding planning target volume 
(PTV) and OARs with the comparison of IGBT and 
VMAT for localized H&N cancer using identical 
CT data and contours.
Patients and methods
Patients’ characteristics
Thirty-eight consecutive patients with T1-4 mobile 
tongue (n = 17), floor of mouth (n = 9) and base of 
tongue (n = 12) cancer treated between January 
2013 and March 2017 at the National Institute of 
Oncology, Budapest, Hungary were selected for 
this study (Table 1). Primary lesions or tumor bed 
were treated with CT image based IGBT alone (n 
= 22) or after EBRT as a boost (n = 16).  All T3-4 
cases (n = 12) were base of tongue cancer treated 
exclusively with radiotherapy (EBRT + BT boost). 
The T4 tumors invaded the deep muscles of the 
tongue, without invasion into the mandible or 
other regions. Tumor excision was carried out in 
18 patients. Ipsi- and contralateral submandibular 
glands (15 and 1) (iSMGs, cSMGs) were removed 
during surgery.
Brachytherapy planning
The process of BT planning was described in de-
tails in our previous publication.12 Under general 
anesthesia in the operating theatre plastic cath-
eters (median 7, range 3–12) were implanted into 
the target volume located in 17 patients on the left, 
in 18 on the right side, and in 3 in the central re-
gion of the tongue/ floor of mouth/base of tongue. 
After implantation, all patients underwent CT 
imaging with 3 mm slice thickness including the 
primary tumor or tumor bed, the spinal cord, pa-
rotid glands (PAGs) on both sides and SMGs. The 
images were transferred to the Oncentra Brachy 
v4.3 (Elekta, Brachytherapy, Veenendaal, The 
Netherlands) treatment planning system.  Gross tu-
mor volume (GTV), clinical target volume (CTV) 
and PTV were contoured on CT images as follows. 
In non-surgical cases (definitive) palpation, visual 
inspection and MR images without CT-MRI fusion 
were used to determine GTV in the patients. CTV 
was defined as GTV + 5mm limited to mandible. 
In postoperative cases CTV was directly defined 
similarly to definitive cases using the preoperative 
MRI. For all cases PTV was the same as CTV with-
out using any margin. Based on CT image sets, the 
mandible, the spinal cord, PAGs on both sides and 
SMGs - as OARs - were delineated. Mandible was 
not part of the PTV. After catheter reconstruction, 
treatment plans were made with geometrical opti-
mization, complemented with graphical optimiza-
tion by adjusting the isodose line in order to appro-
priately cover the PTV by the prescribed dose (PD) 
and keep the doses to OARs as low as possible.13 
Our aim was to obtain less than 0.40 for the dose 
non-uniformity ratio (DNR), the ratio of volumes 
receiving 1.5 times the PD and those receiving the 
PD, (V150/V100). At our institute the fractionation 
schedule was 15 x 3 Gy (45 Gy) for IGBT alone and 
7 x 3 Gy (21 Gy) for IGBT after 50 Gy EBRT.  
VMAT planning
For VMAT plans the same CT images and structure 
set were used as for IGBT. The contours applied for 
 TABLE 1. Dosimetry of PTV
Parameters
IGBT
n=38
VMAT
n=38 p-value
mean S.D. mean S.D.
V95 (%) 92.1 3.0 98.4 0.9 <0.05
V98 (%) 90.2 3.2 90.4 3.7 >0.05
V100 (%) 89.0 3.4 76.7 8.9 <0.05
D90 (%) 98.6 4.7 98.2 0.8 <0.05
D100 (%) 58.6 9.0 87.0 3.2 <0.05
DX = minimum relative dose of the planning dose delivered to X% of the PTV; IGBT = image guided 
high-dose-rate brachytherapy; n = number of patients for analysis; PTV = planning target volume; 
S.D. = standard deviation; VMAT = volumetric modulated arc therapy; VX = relative volume of the 
PTV receiving at least X% of the panning dose 
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IGBT plans were transferred from the Oncentra 
Brachy to the Eclipse v11 (Varian Medical Systems, 
Palo Alto, CA) treatment planning system using 
DICOM RT protocol. Due to this process, all con-
tours of PTV and OARs were identical in both plan-
ning systems. In case of IGBT alone patients VMAT 
was set up for a total dose of 70 Gy (35 x 2 Gy), and 
for EBRT+IGBT patients a total dose of 20 Gy (10 x 
2 Gy) was planned as a boost. VMAT plans were 
created with 6 MV photon energy beams using 
double partial arcs from gantry angle 110° to 250° 
to ensure the homogeneity of PTV dose coverage. 
As regards the dose constraints for OARs and tar-
get volume coverage, VMAT plans were optimized 
using the Varian RapidArc progressive resolution 
optimization algorithm (PRO) and AAA dose cal-
culation algorithm. The objective for PTV was to 
deliver a dose of 95–107% of the PD.  The dose con-
straints for PTV70Gy were as follows: V98% > 90%, 
V95% > 95%, V50% = 100%, V2% < 107%, for the 
spinal cord V2% < 45 Gy, for parotid glands Dmean 
< 24 Gy, for mandible V0.03cc < 70 Gy.
 Dosimetric analysis
Based on dose-volume-histograms (DVHs), treat-
ment plans of both techniques were dosimetrically 
analyzed. For evaluating conformity of dose dis-
tribution to PTV, the relative volume of the PTV 
receiving at least 95, 98 and 100% of the PD (V95, 
V98 and V100) and the minimum relative dose of 
the PD delivered to 90 and 100% of the PTV (D90 
and D100) were calculated. The minimum relative 
doses of the PD delivered to the most exposed 0.1, 
1 and 2 cm3 of the organs ( D0.1cm3, D1cm3 and D2 
cm3) were quantified for the assessment of doses 
to OARs. The salivary glands were classified as 
ipsilateral or contralateral based on the tumor lo-
cation, and were dosimetrically evaluated. For the 
salivary glands, additional parameters such as the 
mean relative dose of the PD delivered to the or-
gans (Dmean), D10, D30, D50, V10, V30 and V50 
were also quantified. The dosimetric data for the 
parotid and submandibular glands were not evalu-
ated for all patients, because in some cases the 
glands were excluded from the field-of-view of the 
CT scans, the volume was too small (for D1 and 
D2cm3 calculation), or the target volume (tumor or 
tumor bed) was centrally located (Tables 4 and 5). 
The spinal cord was not detected in one case be-
cause it was excluded from the field-of-view of the 
CT scans (Table 3).
The mean value with standard deviation was 
used to describe dosimetric parameters for both 
TABLE 2. Dosimetry of mandible and spinal cord
Parameters
IGBT VMAT
p-value
mean S.D. mean S.D.
Mandible, n=38
 D0.1cm3 (%) 77.0 17.2 85.4 7.9 <0.05
 D1cm3 (%) 56.9 13.4 74.5 9.6 <0.05
 D2cm3 (%) 48.4 12.2 68.4 9.5 <0.05
Spinal cord, n=37*
 D0.1cm3 (%) 9.7 2.6 12.3 4.1 <0.05
 D1cm3 (%) 6.8 2.0 10.8 3.7 <0.05
 D2cm3 (%) 5.9 1.9 10.0 3.6 <0.05
DXcm3 = minimum relative dose of the planning dose delivered to most exposed X cm3 of the 
organs; IGBT = image guided high-dose-rate brachytherapy; n = number of patients for analysis; 
S.D. = standard deviation; VMAT = volumetric modulated arc therapy.
*  in one patient the spinal cord was not detected because it was excluded from the field-of-view 
of the CT scans
TABLE 3. Dosimetry of parotid gland
Parameters
IGBT VMAT
p-value
mean S.D. mean S.D.
ipsilateral side (n=34*)
 Dmean (%) 4.6 1.4 4.6 2.6 >0.05
 D0.1cm3 (%) 11.2 2.8 18.0 7.1 <0.05
 D1cm3 (%) 8.1 2.1 12.9 6.3 <0.05
 D2cm3 (%) 7.0 2.0 10.5 5.7 <0.05
 D10 (%) 7.3 2.1 11.2 5.6 <0.05
 D30 (%) 5.5 1.6 5.5 4.0 >0.05
 D50 (%) 4.5 1.3 3.0 3.1 <0.05
 V10 (%) 3.1 4.0 18.0 16.9 <0.05
 V30 (%) 0.0 0.0 0.7 3.9 N.A.
 V50 (%) 0.0 0.0 0.1 0.5 N.A.
contralateral side (n=35**)
 Dmean (%) 3.0 0.9 3.9 2.1 >0.05
 D0.1cm3 (%) 8.9 2.1 15.3 5.9 <0.05
 D1cm3 (%) 5.9 1.6 10.8 5.9 <0.05
 D2cm3 (%) 4.9 1.5 9.1 5.4 <0.05
 D10 (%) 5.4 1.3 9.9 4.4 <0.05
 D30 (%) 4.0 1.0 4.9 3.7 >0.05
 D50 (%) 3.2 0.8 2.2 2.3 <0.05
 V10 (%) 0.5 0.3 14.2 13.2 <0.05
 V30 (%) 0.0 0.0 0.8 4.7 N.A.
 V50 (%) 0.0 0.0 0.2 1.3 N.A.
Dmean = minimum relative dose of the planning dose delivered to the organs; DX = minimum 
relative dose of the planning dose delivered to X% of the PTV; DXcm3 = minimum relative dose 
of the planning dose delivered to most exposed X cm3 of the organs; IGBT = image guided high-
dose-rate brachytherapy; n = number of patients for analysis; N.A. = not available; S.D. = standard 
deviation; VMAT = volumetric modulated arc therapy; VX = relative volume of the PTV receiving 
at least X% of the panning dose
*  in one patient the parotid gland was not detected because it was excluded from the field-
of-view of the CT scans, and in three patients parotid glands were not evaluated because of 
central implantation
** three patients were not evaluated because of central implantation
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techniques, and the data were compared us-
ing the non-parametric Mann-Whitney U test 
with GraphPad Prism version 5.01 for Windows 
(GraphPad Software, San Diego, CA). The level of 
statistical significance was set at p ≤ 0.05.
Results
The dosimetric parameters of PTV are presented 
in Table 2. Dose distribution of BT and VMAT are 
presented in Figure 1. The dose conformity was ex-
cellent with both techniques. V95 was significantly 
better with VMAT (98.4% vs. 92.1%, p < 0.05), but 
V100 was superior with IGBT (89.0% vs. 76.7%, p < 
0.05). V98 was similar in both techniques (90.2% vs. 
90.4% for IGBT and VMAT, p > 0.05, respectively). 
Relative dose coverage to PTV, D90 was statistical-
ly significantly better with IGBT (98.6% vs. 98.2%), 
probably without clinical consequences. However, 
D100 showed a reverse result (58.6% vs. 87.0%).
As for OARs, the mandible and the spinal cord 
were better protected by IGBT (Table 3). For doses 
to small volumes (D0.1cm3, D1cm3 and D2cm3) sig-
nificantly lower values were obtained with IGBT 
(e.g. D0.1cm3 was 77.0% vs. 85.4% and 9.7% vs. 
12.3% to the mandible and the spinal cord). 
Doses to the salivary glands were generally 
lower with IGBT (Tables 4 and 5). Six parameters 
of ipsilateral PAGs (iPAGs) were significantly low-
er with IGBT than with VMAT (e.g. D0.1cm3 was 
11.2% vs. 18.0%, D10 was 7.3% vs. 11.2% and V10 
was 3.1% vs. 18.0%, respectively) (Table 4). Two 
parameters (Dmean and D30) were identical for 
the two techniques (4.6% and 5.5%). Parameters of 
contralateral PAGs (cPAGs) showed the same ten-
dency as iPAGs (Table 4). Dosimetry of iSMGs indi-
cated that doses with IGBT were smaller than with 
VMAT, but no significant differences were found 
between the two techniques (Table 5). All dose pa-
rameters of cSMGs were significantly smaller with 
IGBT than with VMAT (e.g. Dmean was 8.2% vs. 
16.9%, D10 was 11.1% vs. 25.3% and V10 was 26.0% 
vs. 69.9%, respectively) (Table 5). 
Discussion
The comparison of new technologies in the H&N 
region is a very interesting area of research.7 Sresty 
et al. compared plans of IGBT and IMRT for mo-
bile tongue cancer directly, and found a very good 
dose conformity between the two techniques.14 Our 
study also revealed good target coverage with both 
TABLE 4. Dosimetry of submandibular gland
Parameters
IGBT VMAT
p-value
mean S.D. mean S.D.
ipsilateral side
 Dmean (%), n=20* 16.4 10.7 21.9 19.9 >0.05
 D0.1cm3 (%), n=20* 27.4 15.6 39.9 23.3 >0.05
 D1cm3 (%), n=18** 19.4 11.2 27.2 17.6 >0.05
 D2cm3 (%), n=17** 16.1 9.4 20.8 14.7 >0.05
 D10 (%), n=20* 22.6 13.9 33.2 23.0 >0.05
 D30 (%), n=20* 18.3 11.7 25.8 21.9 >0.05
 D50 (%), n=20* 15.7 10.4 21.0 20.9 >0.05
 V10 (%), n=20* 61.3 38.6 63.9 33.6 >0.05
 V30 (%), n=20* 14.5 28.0 30.1 38.7 >0.05
 V50 (%), n=20* 1.4 3.7 14.1 27.4 >0.05
contralateral side
 Dmean (%), n=34*** 8.2 4.8 16.9 10.8 <0.05
 D0.1cm3 (%), n=34*** 13.4 5.3 29.7 12.0 <0.05
 D1cm3 (%), n=32**** 9.4 3.2 21.7 8.6 <0.05
 D2cm3 (%), n=32**** 8.1 2.9 18.3 8.3 <0.05
 D10 (%), n=34*** 11.1 5.6 25.3 12.2 <0.05
 D30 (%), n=34*** 9.2 5.1 20.4 11.4 <0.05
 D50 (%), n=34*** 8.0 4.7 16.7 11.4 <0.05
 V10 (%), n=34*** 26.0 30.2 69.9 27.5 <0.05
 V30 (%), n=34*** 1.2 7.0 14.1 25.1 <0.05
 V50 (%), n=34*** 0.0 0.0 2.7 12.1  N.A.
Dmean = minimum relative dose of the planning dose delivered to the organs; DX = minimum 
relative dose of the planning dose delivered to X% of the PTV; DXcm3 = minimum relative dose 
of the planning dose delivered to most exposed X cm3 of the organs; IGBT = image guided high-
dose-rate brachytherapy; n = number of patients for analysis; N.A. = not available; S.D. = standard 
deviation; VMAT = volumetric modulated arc therapy; VX = relative volume of the PTV receiving 
at least X% of the panning dose
*   in fifteen patients the submandibular glands were resected by operation and three patients were 
not evaluated because of central implantation.
**  two and three patients, respectively, were additionally excluded from the analysis of D1cm3 and 
D2cm3 because the volume was too small.
***  in one patient the submandibular gland was resected by operation and three patients were not 
evaluated because of central implantation.
****  two and two patients, respectively, were additionally excluded from the analysis of D1cm3 and 
D2cm3 because the volume was too small.
FIGURE 1. Representative dose distribution of (A) image guided high-dose-rate 
brachytherapy (IGBT) and (B) volumetric modulated arc therapy (VMAT).
A B
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IGBT and VMAT. Our results confirmed that the 
volumes irradiated by 100% of the PD were larger 
and the dose gradient around PTV was higher with 
IGBT than with VMAT - because of the physical 
characteristics of BT. Moreover, IGBT yielded bet-
ter values in D90, but worse in D100. The major-
ity of locoregional treatment failures occur within 
the target volumes irradiated with high doses by 
IMRT.15,16 These regions are thought to represent 
areas of hypoxia and radiation resistant tumor 
cells, and may require higher doses to improve lo-
cal control.17 These observations might support the 
theory that the PTV of the primary tumor or tumor 
bed - if it is technically feasible - can be treated with 
IGBT.
Owosho et al. analyzed oral and oropharyngeal 
cancer patients and 96% of the osteoradionecrosis 
(ORN) affected regions of the jaw received doses 
over 60 Gy, suggesting >60 Gy as a threshold for 
ORN risk.18 In the current research mean D0.1cm3 
of the mandible was 85.4% with VMAT, so 0.1cm3 
received at least 59.8 Gy (70 Gy x 0.854). The man-
dible was significantly better protected with IGBT 
than with VMAT, due to intensity modulation with 
stepping source technology avoiding high irradia-
tion of the mandible.1 IGBT provided safe and se-
cure treatment for the mandible. 
For tonsillar cancer patients Stieler et al. report-
ed 41.6 Gy and 42.6 Gy as mean maximum dose 
to the spinal cord with IMRT (9 fields) and VMAT 
(single arc), respectively, including the neck region 
in the treatment fields.19 In the direct comparison of 
plans of IGBT and IMRT for mobile tongue cancer, 
Sresty et al. reported maximum doses to the spi-
nal cord from 9% to 14% with IGBT, whereas from 
15.6% to 24.6% with IMRT.14 Meanwhile our results 
of mean D0.1cm3, which represents the maximum 
dose to the spinal cord, showed 9.7% (4.4 Gy) with 
IGBT and 12.3% (8.6 Gy) with VMAT (p < 0.05). The 
results were similar and doses to the spinal cord 
were acceptable for both techniques in patients, in 
whom only the primary lesion was irradiated. 
Dose to PAGs is important in terms of xerosto-
mia, because they produce up to 70% of the total 
stimulated saliva.20-23  Owosho et al. analyzed the 
role of PAGs irradiation in the development of se-
vere xerostomia defined as Grade 4 according to 
the LENT SOMA scales after IMRT, and reported 
that xerostomia occurred in a follow-up time of 
<6 months, when the Dmean to iPAG and cPAG 
was 43.8 Gy and 24.9 Gy, respectively.23 They con-
cluded that the incidence of xerostomia could be 
decreased by limiting the mean dose to both PAGs 
to values below 25 Gy. In our study the mean doses 
to iPAG and cPAG were 4.6% (3.2 Gy) and 3.9% (2.7 
Gy) with VMAT and 4.6% (2.1 Gy) and 3.0% (1.4 
Gy) with IGBT, respectively. Dose delivery to PAGs 
by both techniques probably has a little impact on 
xerostomia in patients, whose PTV includes only 
the primary tumor or tumor bed, but in IGBT the 
dose to PAGs was somewhat lower. Maintenance 
of adequate SMG function is also important in the 
reduction of xerostomia because SMGs produce 
about 20% to 30% of salivary output, including up 
to 90% of unstimulated salivary output.24-27 Wang 
et al. reported SMG dosimetry using IMRT with or 
without cSMG sparing.27 In their study the mean 
doses to iSMGs and cSMGs were 60.8 Gy and 20.4 
Gy, in the cSMG-sparing group as opposed to the 
unspared group, where these parameters were 60.9 
Gy and 57.4 Gy, respectively. They observed that 
xerostomia grades at 2 and 6 months post-IMRT 
were significantly lower among patients in the 
cSMG-sparing group than in the unspared group. 
In our study all parameters of cSMGs were smaller 
with IGBT than with VMAT (p < 0.05). Dmean of 
cSMGs with VMAT was 16.9% (11.8 Gy). Dmean 
of cSMGs with IGBT was 8.2% (3.7 Gy), about one 
third of the value with VMAT, so IGBT had a more 
significant effect on dose reduction to cSMGs. 
A major source of concern with VMAT and 
IMRT is the higher low dose radiation to surround-
ing normal tissue, which potentially increases the 
risk of secondary malignancy.17 As for our results, 
V10 with VMAT was appreciably large especially 
for PAG. Immobilization for precise irradiation 
and the possibility of tumor repopulation during 
the long treatment time can also be a problem with 
VMAT. On the other hand, technique sensitivity 
is one of the drawbacks of IGBT. However, some 
measures have been introduced for easy implanta-
tion, such as the use of a vinyl template or ultra-
sound guided technique.5
One of the limitations of our study is that the 
Task Group (TG)-43 formalism, implemented in 
our planning system for dose calculation,  has not 
taken into consideration tissue heterogeneities.28 
However, Peppa et al. revealed that the absolute 
differences in the parameters are too small to war-
rant clinical importance in terms of tumor control 
or complication probabilities.29 The second draw-
back is that the catheters in the target have a small 
tissue inhomogeneity effect. However, according to 
our investigation the variations in density in small 
volumes cause less than a 0.5% change in dosim-
etry. We are aware of that in EBRT the PTV should 
be larger than in BT, but our aim was to make com-
parison between two largely different irradiation 
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techniques, and since the same PTVs were used in 
plans of both treatment modalities in our study the 
dosimetric results apply only to the differences be-
tween BT and VMAT.
Though this article deals with the dosimetric and 
not the therapeutic comparison of the above men-
tioned two techniques, we would like to emphasize 
that the fractionation schedule, which we used in 
our BT treatment, was based on the European and 
American recommendations, where the suggested 
boost dose is 21-30/3 Gy with HDR after 45–50 
Gy EBRT and the definitive dose is 45–60/3 Gy.2,30 
Using alfa/beta = 10 Gy and without taking into 
consideration the time factor, the calculated bio-
logical effective dose (BED) for BT alone (15 x 3 Gy) 
was 58.5 Gy, for EBRT (25 x 2 Gy) and BT boost (7 x 
3 Gy) 87.3 Gy (60 Gy + 27.3 Gy), for EBRT alone (35 
x 2 Gy) 84 Gy and for EBRT (25 x 2 Gy) and EBRT 
boost (10 x 2 Gy) 84 Gy (60 Gy + 24 Gy). We applied 
lower BT dose for BT alone because of the lack of 
long-term experiences with HDR BT. 
Conclusions
This is the first study with direct dosimetric com-
parison between IGBT and VMAT for H&N can-
cer applying various parameters. Both techniques 
provided excellent target coverage, but IGBT 
was found superior in protecting OARs. Adverse 
events, such as xerostomia and osteoradionecro-
sis, derived from irradiation of OARs could be se-
rious problems in the H&N cancer radiotherapy. 
Therefore, it is clinically important to keep the dose 
for OARs as low as possible. In this respect the re-
sults confirm the important role of interstitial RT 
in the era of new external beam RT techniques. To 
translate the results of these dosimetric findings 
into clinical practice, more patients and long term 
follow-up with prospective collection of toxicities 
are necessary.
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